Not Enough Evidence to Balance Harms, Benefit of Visual Skin Cancer Exam
There is currently not enough evidence to assess the balance of benefits and harms of a visual skin examination by a clinician to screen for skin cancer in asymptomatic adults.
The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update: Hydrochlorothiazide: risk of non-melanoma skin cancer, particularly in long-term use...
DiscussionChronic inflammation can promote cell proliferation and growth. The use of immunomodulatory drugs is associated with an increased risk of developing melanoma and non-melanoma skin cancer. The two patients described in this report both had long-standing IBD treated with immunomodulatory drugs. It seems reasonable to suggest that these two factors may have promoted the development of uveal melanoma. More studies are warranted to investigate and confirm this possible association.
CONCLUSIONS: Inverse associations between circulating Treg cells and gamma HPV infection suggest that localised viral infection may promote immunosuppressive cell migration into skin. This article is protected by copyright. All rights reserved. PMID: 30431148 [PubMed - as supplied by publisher]
Abstract Radiotherapy plays a role in the definitive or adjuvant management of early and late stage skin cancers including nonmelanoma basal cell carcinoma and cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The role of radiotherapy in skin cancers of the head and neck is reviewed including early and advanced-stage nonmelanoma skin cancers, melanoma, and Merkel cell carcinoma. In particular, the indications, oncologic outcomes, and technical aspects of radiotherapy for these diseases are discussed. PMID: 30420066 [PubMed - in process]
This study examines the oncological safety of the new model.
Skin cancer remains the most common cancer in the United States, affecting approximately 20% of Americans during their lifetime. Despite major advances in care delivery, including targeted drug therapies and immunotherapy, the primary treatment for early nonmelanoma skin cancer (NMSC) and melanoma continues to be careful surgical extirpation with clear margins, along with meticulous reconstruction that optimally addresses functional and aesthetic deficits.
Radiotherapy plays a role in the definitive or adjuvant management of early and late stage skin cancers including nonmelanoma basal cell carcinoma and cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The role of radiotherapy in skin cancers of the head and neck is reviewed including early and advanced-stage nonmelanoma skin cancers, melanoma, and Merkel cell carcinoma. In particular, the indications, oncologic outcomes, and technical aspects of radiotherapy for these diseases are discussed.
Invasive melanoma survivors have an increased risk of developing second primary cancers, however, similar risks associated with in situ melanoma haven ’t been established.We evaluated 43,829 first primary in situ melanoma survivors diagnosed from 1982-2012 in Queensland, Australia. Risk of second non-melanoma primary cancers was estimated from standardized incidence ratios with 95% confidence intervals.A total of 4,917 (11.3%) in situ melanoma s urvivors developed a second primary cancer. No net increased risk compared with the general population was found.
This article gives an overview on the epidemiology of cutaneous melanoma of the skin and nonmelanoma skin cancer, on the history and practice of the current program, and appraises the evidence of screening for skin cancer based on a selective search for literature and data.The incidence of skin cancer has increased markedly throughout the last decades. The available evidence indicates efficacy of screening for skin cancer, but on a low level. Randomized controlled trials are lacking and the available evidence is based largely on the pilot study SCREEN which was conducted in 2003/2004 in Schleswig-Holstein, German...
Publication date: Available online 7 November 2018Source: Actas Dermo-Sifiliográficas (English Edition)Author(s): A. Alegre-Sánchez, N. Jiménez-Gómez, P. BoixedaAbstractAbsorption of topical products through the epidermis is limited by the skin's barrier function. Numerous techniques and agents such as microneedling, dermabrasion, radiofrequency, and lasers have been used to increase penetration within an approach known as transdermal drug delivery. One of these techniques is laser-assisted drug delivery (LADD), which often uses ablative fractional lasers (CO2 or erbium:YAG lasers) because of th...